HAMPTON, N.J., Jan. 29, 2015 /PRNewswire/ -- Bellerophon Therapeutics, LLC, a clinical stage biotherapeutics company, today announced that it has strengthened its drug and device development capabilities with the recent additions of Deborah A. Quinn, M.D., as Vice President and Medical Lead for the INOpulse programs and Martin Dekker as Vice President of Device Engineering. Both are newly created positions on the Bellerophon Executive Team.
Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics, noted, "We are delighted to welcome both Debbie and Martin to Bellerophon, at an exciting juncture for the company. Debbie's significant experience leading the pulmonary arterial hypertension (PAH) program for Novartis Pharmaceuticals AG, combined with her tenures as a physician at Massachusetts General Hospital and Harvard Medical School, where she focused on pulmonary and critical care medicine, make her a natural choice as the medical lead of our INOpulse programs. For his part, Martin brings to Bellerophon nearly two decades of experience in medical device development and manufacturing, most recently at Spacelabs Healthcare, where he successfully lead the development and production of numerous new products. As we start to move our INOpulse program into Phase 3 development for PAH and prepare for top-line results in mid-2015 for BCM, our investigational treatment for preventing cardiac remodeling and subsequent Chronic Heart Failure (CHF) following an acute myocardial infarction, commonly known as a heart attack, these key additions to our team reflect our continued commitment to developing innovative new products at the intersection of drugs and devices."
Prior to joining Bellerophon, from December 2006 to April 2013, Dr. Quinn was responsible for leading global clinical trials in PAH at Novartis, and, from 2013 to 2015, served as a Medical Director for Novartis' heart failure programs. From 1998 to 2011, Dr. Quinn was a practicing physician at Massachusetts General Hospital. In addition, she served as an Instructor In Medicine at Harvard Medical School from 1998 to 2006 and as a Clinical Assistant Professor in Medicine from 2006 to 2011. She has focused on caring for patients suffering from PAH while also leading basic research in the area of pulmonary vasculature. Dr. Quinn received her M.D. from the University of Massachusetts Medical School in Worchester, Massachusetts, and completed her postdoctoral training in Medicine and Pulmonary and Critical Care Fellowship at Massachusetts General Hospital.
Mr. Dekker has more than 18 years of experience in medical device development and manufacturing in the United States, United Kingdom and the Netherlands. He joined Bellerophon from Spacelabs Healthcare, where he held several positions, including his most recent role as Director of Global Operations Engineering. During his employment with Spacelabs, Mr. Dekker was successful in leading and co-designing new products, implementing production line design enhancements and driving numerous quality/engineering improvement projects. He holds a Bachelor's Degree in Electronics from Noordelijke Hogeschool Leeuwarden, the Netherlands, and is a member of the Institute of Electrical and Electronic Engineers.
Bellerophon Therapeutics LLC, is a privately-held, clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse, one for the treatment of Pulmonary Arterial Hypertension (PAH) for which the company intends to commence Phase 3 clinical trials in the second half of 2015 and a second for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) which is in Phase 2 development. Bellerophon acquired exclusive worldwide rights to develop and commercialize the INOpulse programs in PAH, PH-COPD and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) from Ikaria, Inc. in February 2014 as part of Ikaria's spin-out of certain of its research and development assets and subsidiaries. Bellerophon's other program is bioabsorbable cardiac matrix, or BCM, which is being developed for the prevention of cardiac remodeling and subsequent chronic heart failure (CHF) following acute myocardial infarction, commonly known as a heart attack. BCM is currently in development in a placebo-controlled clinical trial designed to support CE mark registration in the European Union. This trial recently completed enrollment in December 2014, with 303 patients having completed the treatment procedure, and top line results are expected in mid-2015. Bellerophon has an exclusive worldwide license to BCM from BioLineRx Ltd.
SOURCE Bellerophon Therapeutics LLC